肿瘤预防与治疗2023，Vol.36Issue(12)：998-1002,5.DOI:10.3969/j.issn.1674-0904.2023.12.003
免疫原发耐药的复杂难治性肺癌应对策略
Countermeasures of Primary Immune Resistance in Refractory Lung Cancer
摘要
Abstract
Refractory lung cancer refers to a series of lung cancers which are difficult to be diagnosed and treated and with complex biological background caused by various reasons.Primary immune resistance in refractory lung cancer is a dif-ficult clinical concern due to its lack of predictive markers,poor clinical response,and rapid progression.It mainly stems from endogenous factors,exogenous factors and host factors.As for different mechanisms of primary immune resistance,there are different countermeasures to guide clinical practice.This review described the definition,mechanism,solution and prospect of primary immune resistance in refractory lung cancer,and provides novel options to address immune resis-tance.关键词
肺恶性肿瘤/免疫检查点抑制剂/原发性免疫耐药/肿瘤免疫微环境Key words
Lung cancer/Immune checkpoint inhibitors/Primary immune resistance/Immune microenvironment分类
医药卫生引用本文复制引用
王柯,刘洋,贾蓉,王绎,谢华,周进..免疫原发耐药的复杂难治性肺癌应对策略[J].肿瘤预防与治疗,2023,36(12):998-1002,5.基金项目
This study was supported by grants from Guangdong Association of Clinical Trials(GACT)/Chinese Thoracic Oncology Group(CTONG)and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer(No.YC20210105) （GACT）
and by grants from Chinese Society of Clinical Oncology(No.Y-2021AST/zd-0119). 广东省临床试验协会/中国胸部肿瘤研究协作组和广东省肺癌转化医学重点实验室开放课题(编号:YC20210105) （No.Y-2021AST/zd-0119）
2022CSCO重点项目(编号:Y-2021AST/zd-0119) （编号:Y-2021AST/zd-0119）
